Why PreludeDx’s second FDA breakthrough device designation matters for precision diagnostics
Breast cancer care needs sharper radiation decisions. PreludeDx’s AidaBREAST now faces the harder test of validation, adoption and access.
How AidaBreast’s multi-omic insights may reduce overtreatment in breast cancer care
Prelude Corporation has announced the first independent validation of AidaBreast, a multi-omic diagnostic test developed to predict both locoregional recurrence risk and individualized radiation therapy benefit in early-stage hormone receptor-positive, HER2-negative invasive breast cancer. The study, conducted at Royal Melbourne Hospital and presented at the San Antonio Breast Cancer Symposium 2025, evaluated over 400 women […]